Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
7.93
-1.20 (-13.14%)
At close: Nov 2, 2026, 4:00 PM EST
7.77
-0.16 (-2.00%)
After-hours: Nov 2, 2026, 7:32 PM EST
Bicara Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Bicara Therapeutics stock has a consensus rating of "Buy" and an average price target of $33.92. The average 1-year stock price forecast is 327.74% higher than the current stock price, while the lowest is $8.00 (+0.88%) and the highest is $45 (+467.47%).
Price Target: $33.92 (+327.74%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Bicara Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 10 | 10 | 10 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 3 | 3 | 3 | 3 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Total | 15 | 15 | 15 | 16 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Sell Downgrades $8 | Sell | Downgrades | $8 | +0.88% | Oct 29, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $45 | Buy | Maintains | $45 | +467.47% | Oct 29, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $34 | Buy | Maintains | $34 | +328.75% | Oct 27, 2026 |
| BTIG | BTIG | Buy Maintains $39 | Buy | Maintains | $39 | +391.80% | Oct 27, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $33 | Buy | Maintains | $33 | +316.14% | Oct 26, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.39
from -2.52
EPS Next Year
-3.52
from -3.39
EPS and Forward PE are based on non-GAAP adjusted numbers.